Antithrombotic therapy before, during and after transcatheter aortic valve replacement (TAVR)

J Thromb Thrombolysis. 2015 May;39(4):467-73. doi: 10.1007/s11239-014-1118-x.


Transcatheter aortic valve replacement (TAVR) has been emerged as a promising alternative for the management of patients with severe AS who otherwise are deemed inappropriate candidates for surgery. Post procedural thromboembolic events and risk of bleeding continue to be a significant challenge in managing patients who underwent TAVR. This article systematically reviews the evidence, current guidelines and upcoming studies investigating antithrombotic therapy before, during and after TAVR.

Publication types

  • Review

MeSH terms

  • Aortic Valve Stenosis / therapy*
  • Fibrinolytic Agents / therapeutic use*
  • Humans
  • Perioperative Care / methods*
  • Transcatheter Aortic Valve Replacement*


  • Fibrinolytic Agents